Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISC 2023 | ISC 2023 highlights: ANGEL-ASPECT & SELECT2

The International Stroke Conference (ISC) 2023 featured the presentation of anticipated data from global clinical trials investigating prehospital management, endovascular treatment, neuroprotection, rehabilitation, and prevention. Marc Ribo, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, highlights some of the key news from ISC 2023 with immediate implications for clinical practice. The ANGEL-ASPECT (NCT04551664) and SELECT2 (NCT03876457) trials both investigated the value of endovascular therapy (EVT) for acute ischemic stroke with a large infarct core. Patients with an acute ischemic stroke due to large vessel occlusion with an ASPECT score of 3-5 or core volume of 70-100ml (ANGEL-ASPECT)/ ≥50ml (SELECT2) were randomized to receive EVT or best medical management (BMM) within 24 hours from last known well. Improved mRS scores at 90 days were seen with EVT use compared to BMM in both trials. This interview took place during the International Stroke Conference (ISC) 2023 in Dallas, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


MR is a consultant for Apta Targets.